Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Nota Laboratories LLC
Profile last edited on: 3/3/2023      CAGE: 75RS6      UEI: C1HCRNLZT417

Business Identifier: Treatments for chronic rhinosinusitis
Year Founded
2014
First Award
2015
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

600 South Wagner Road Suite 6
Ann Arbor, MI 48103
   (860) 227-2717
   N/A
   www.notalabs.com
Location: Single
Congr. District: 06
County: Washtenaw

Public Profile

Nota Laboratories is developing a highly effective nasal rinse that can treat chronic rhinosinusitis (CRS). CRS is estimated to have direct costs exceeding $ billion annually and additionally causing millions of limited activity days. NOTA Laboratories LLC has identified safe and naturally occurring therapeutic agents that can enhance the levels of nitric oxide (NO) in the sinus airways.NO has been proven to stimulate mucociliary clearance and reduces microbial biofilm formation.

Extent of SBIR involvement

User Avatar
Phase I Awards
5
Phase II Awards
3
Conversion Rate
60.00%
Phase I Dollars
$1,157,851
Phase II Dollars
$3,298,292
Total Awarded
$4,456,143

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2023 2 NIH $1,989,169
Project Title: Photochemical Generation of Gas Phase Nitric Oxide from ImmobilizedS-Nitrosothiols for Biomedical Applications
2022 2 NIH $1,072,913
Project Title: Low Cost Electrochemical Gas Phase Nitric Oxide Generator for Biomedical Applications
2019 1 NIH $224,943
Project Title: Extended Nitric Oxide Delivery Device to Reduce/Prevent Tunneled Dialysis Catheter Infections
2018 1 NIH $233,275
Project Title: Antimicrobial Intravascular Catheter Lock Solutions Based on Endogenous Nitric Oxide Release Agent
2018 2 NIH $1,737,539
Project Title: S-Nitrosothiol-Based Rinse/Aerosol Solutions for Treatment/Prevention of Rhinosinusitis

Key People / Management

  Malcolm Kahn -- President And Chief Executive Officer

  Rebecca Dahler -- VP Operations

  Danial Drake -- Chief Medical Officer

  Joan Keiser -- Regulatory Affairs

  Glenn Martin -- VP R&D

  Marc B Meyerhoff -- Chief Technology Officer

  Eric Pfitzenmaier -- Director Quality

  Paul Rabinovitch

  Umadevi Sajjan

  Alexander Wolf

Company News

There are no news available.